Signature Estate & Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Signature Estate & Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$238K	Buy	+478	New	+$212K	﹤0.01%	607

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Signature Estate & Investment Advisors's VRTX Position: Q2 2026 in Review

Signature Estate & Investment Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 478 shares worth $238K. The stake represents ﹤0.01% of the portfolio and ranks #607 among its holdings.

1,091 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Signature Estate & Investment Advisors held 478 shares of Vertex Pharmaceuticals worth $238K as of Q2 2026.
Vertex Pharmaceuticals was a new Signature Estate & Investment Advisors position in Q2 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Signature Estate & Investment Advisors's portfolio in Q2 2026, its #607 holding.
1,091 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Signature Estate & Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.